Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola (Naples, Italy). Recommendations of the ATS/ERS Task Force for the definition of outcomes for COPD pharmacological trials. Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers

Member's Comments

No comment yet.

Related content which might interest you: Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol Source: ERJ Open Res, 6 (3) 00193-2020; 10.1183/23120541.00193-2020 Year: 2020 Monitoring of COPD. A review of current guidelines‘ recommendations Source: Annual Congress 2007 - Management of COPD: pushing forward the boundaries in primary care Year: 2007 ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations Source: Guideline 2022 Year: 2021 Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006 Chronic obstructive pulmonary disease (COPD) assessment service: guidelines for referral and accuracy of clinical assessment Source: Eur Respir J 2005; 26: Suppl. 49, 299s Year: 2005 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: 243-244 Year: 2002 COPD severity analysis according to current evaluation criteria – National survey Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice Source: Eur Respir J 2013; 41: 1252-1256 Year: 2013 Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study Source: Eur Respir J 2009; 34: 588 Year: 2009 Practical recommendations for exercise training in patients with COPD Source: Eur Respir Rev 2013; 22: 178-186 Year: 2013 Adherence to national (UK) respiratory guidelines in general practice Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care Year: 2007 Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 903-908 Year: 2001 Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care Source: Eur Respir J 2008; 32: 945-952 Year: 2008 Socioeconomic status shaping GOLD A-D classification in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Distribution of COPD phenotypes according to the Spanish COPD guidelines in clinical practice Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Disease progression and changes in risk groups' classification over a period of one year in the GPs based Swiss chronic obstructive pulmonary disease (COPD) cohort Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care Year: 2014 International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Source: ERS Webinar 2020: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Year: 2020 International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Source: Eur Respir J 2014; 43: 343-373 Year: 2013 Evaluation of the GOLD 2011 severity criteria across the COPD spectrum Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013